Evidence map›Paper›PMID 40610080›Full record

ReviewThe Urologic clinics of North America2025

Hyperoxaluria: Diagnosis and Treatment.

Owen P Cunneely, Feres Camargo Maluf, Sonia Fargue, John Knight, Dean G Assimos, Kyle D Wood

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Urologic clinics of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Owen P CunneelySchool of Medicine, University of Alabama at Birmingham, FOT 1120 1720 2nd Avenue South, Birmingham, AL 35294-3411, USA.
Feres Camargo MalufDepartment of Urology, University of Alabama at Birmingham, FOT 1120 1720 2nd Avenue South, Birmingham, AL 35294-3411, USA. Electronic address: fcamargomaluf@uabmc.edu.
Sonia FargueDepartment of Urology, University of Alabama at Birmingham, FOT 1120 1720 2nd Avenue South, Birmingham, AL 35294-3411, USA.
John KnightDepartment of Urology, University of Alabama at Birmingham, FOT 1120 1720 2nd Avenue South, Birmingham, AL 35294-3411, USA.
Dean G AssimosDepartment of Urology, University of Alabama at Birmingham, FOT 1120 1720 2nd Avenue South, Birmingham, AL 35294-3411, USA.
Kyle D WoodDepartment of Urology, University of Alabama at Birmingham, FOT 1120 1720 2nd Avenue South, Birmingham, AL 35294-3411, USA.

Funding

Oxalobacter formigenes colonization and oxalate excretion in calcium oxalate kidney stone diseaseR01DK087967 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KNIGHT, JOHN · 2011 to 2020
$3.5M
Hydroxyproline Dehydrogenase Inhibitors for the Treatment of Primary HyperoxaluriaR01DK137305 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI W TODD LOWTHER · 2024 to 2026
$2.0M
NIDDK NIH HHS R01 DK087967NIDDK NIH HHS R01 DK137305
6 · The paper itself

Abstract

Hyperoxaluria is categorized as either primary (PH), enteric (EH), or idiopathic (IH). The PHs are a group of ultra-rare genetic disorders resulting in oxalate overproduction that can result in end-stage renal disease (ESRD). Novel RNA inhibitory drugs are now available to treat PH that significantly reduced the risk of kidney stones. EH is driven by fat malabsorption and enhanced intestinal oxalate absorption, which in severe cases can result in ESRD. Therapies for EH are limited and research is focused on novel strategies to reduce intestinal oxalate absorptions. Causes for IH are unclear and may involve multiple mechanisms.

Indexed as

HyperoxaluriaHumansKidney Failure, ChronicOxalatesOxalatesEnteric hyperoxaluriaHyperoxaluriaKidney stonesOxalatePrimary hyperoxaluriaUrolithiasis

Identifiers

PMID40610080
PMCPMC13242797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.